CoChat

SMAD-Independent Down-Regulation of Caveolin-1 by TGF-β: Effects on Proliferation and Survival of Myofibroblasts

Open access

The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.

Abstract

Transforming growth factor-β (TGF-β) mediates growth-inhibitory effects on most target cells via activation of the canonical SMAD signaling pathway. This growth-inhibitory activity may be coupled with cellular differentiation. Our studies demonstrate that TGF-β1 inhibits proliferation of primary, non-transformed human lung fibroblasts in association with the induction of myofibroblast differentiation. Differentiated myofibroblasts maintain the capacity to proliferate in response to exogenous mitogenic stimuli and are resistant to serum deprivation-induced apoptosis. These proliferative and anti-apoptotic properties of myofibroblasts are related, in part, to the down-regulation of caveolin-1 (Cav-1) by TGF-β1. Cav-1 down-regulation is mediated by early activation of p38 MAPK and does not require SMAD signaling. In contrast, myofibroblast differentiation is dependent on activation of the SMAD pathway, but not on p38 MAPK. Thus, combinatorial signaling by TGF-β1 of myofibroblast differentiation and down-regulation of Cav-1 by SMAD and p38 MAPK pathways, respectively, confer proliferative and apoptosis-resistant properties to myofibroblasts. Selective targeting of this SMAD-independent, p38-MAPK/Cav-1-dependent pathway is likely to be effective in the treatment of pathological conditions characterized by TGF-β signaling and myofibroblast activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0116995

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 TGF-β1 induces growth suppression in association with induction of myofibroblast differentiation of human lung fibroblasts. A, Early passage human lung fibroblasts (IMR-90), seeded at equal density on 35 mm dishes and grown to 50% confluence, were treated with or without TGF-β1 (2 ng/ml) in the presence/absence of the ALK5 inhibitor (SB431542, 0.5 μM) in 10% FBS for 48 h prior to assessments of cell numbers by Coulter counting (n = 6 per group). Results are averages of at least three independent experiments. Data are presented as mean±S.E.M. **indicates p < 0.01 vs. control cells or cells treated with TGF-β and SB431542. B, IMR-90 cells as described in (A) were grown in 96-well plates and labeled with BrdU for 24 h prior to assays for BrdU incorporation (n = 6 per group). Results are averages of at least three independent experiments. Data are presented as mean±S.E.M. **indicates p < 0.01 vs. control cells or cells treated with TGF-β and SB431542. C, IMR-90 cells grown in 10% FBS were stimulated with or without TGF-β1 (2 ng/ml) in the presence/absence of SB431542 (0.5 μM) for 48 h. Cell lysates were subjected to SDS-PAGE and immunoblotted with an antibody against Cyclin D1; the blot was then stripped and probed for α-smooth muscle actin (α-SMA) and β-actin. D, IMR-90 cells as described in (A) were stimulated with or without TGF-β1 (2 ng/ml) for the indicated times. Western immunoblotting was performed with a monoclonal antibody against α-SMA; the blot was stripped and probed for β-actin. E, Immunofluorescent images of IMR-90 cells treated 24h with vehicle only control, TGF-β only (2ng/ml) and TGF-β (2ng/ml) with SMAD inhibitor (SB431542, 0.5 μM). Cells were stained with antibody specific for α-SMA (1:100) with Alexa flour 594 conjugated secondary antibody (red); and 4′,6-diamidino-2-phenylindole (DAPI, 300nM in PBS) staining was used to identify the nucleus (blue). Representative microscopy images are shown. Magnification of ×40, figures were obtained with a Zeiss Axiovert fluorescence microscope. F, α-SMA expression by western blot in IMR-90 cells treated 24h with vehicle only control, TGF-β only (2ng/ml) and TGF-β (2ng/ml) with SMAD inhibitor (SB431542, 0.5 μM). β-actin is used as loading control.
Figure 1 TGF-β1 induces growth suppression in association with induction of myofibroblast differentiation of human lung fibroblasts. A, Early passage human lung fibroblasts (IMR-90), seeded at equal density on 35 mm dishes and grown to 50% confluence, were treated with or without TGF-β1 (2 ng/ml) in the presence/absence of the ALK5 inhibitor (SB431542, 0.5 μM) in 10% FBS for 48 h prior to assessments of cell numbers by Coulter counting (n = 6 per group). Results are averages of at least three independent experiments. Data are presented as mean±S.E.M. **indicates p < 0.01 vs. control cells or cells treated with TGF-β and SB431542. B, IMR-90 cells as described in (A) were grown in 96-well plates and labeled with BrdU for 24 h prior to assays for BrdU incorporation (n = 6 per group). Results are averages of at least three independent experiments. Data are presented as mean±S.E.M. **indicates p < 0.01 vs. control cells or cells treated with TGF-β and SB431542. C, IMR-90 cells grown in 10% FBS were stimulated with or without TGF-β1 (2 ng/ml) in the presence/absence of SB431542 (0.5 μM) for 48 h. Cell lysates were subjected to SDS-PAGE and immunoblotted with an antibody against Cyclin D1; the blot was then stripped and probed for α-smooth muscle actin (α-SMA) and β-actin. D, IMR-90 cells as described in (A) were stimulated with or without TGF-β1 (2 ng/ml) for the indicated times. Western immunoblotting was performed with a monoclonal antibody against α-SMA; the blot was stripped and probed for β-actin. E, Immunofluorescent images of IMR-90 cells treated 24h with vehicle only control, TGF-β only (2ng/ml) and TGF-β (2ng/ml) with SMAD inhibitor (SB431542, 0.5 μM). Cells were stained with antibody specific for α-SMA (1:100) with Alexa flour 594 conjugated secondary antibody (red); and 4′,6-diamidino-2-phenylindole (DAPI, 300nM in PBS) staining was used to identify the nucleus (blue). Representative microscopy images are shown. Magnification of ×40, figures were obtained with a Zeiss Axiovert fluorescence microscope. F, α-SMA expression by western blot in IMR-90 cells treated 24h with vehicle only control, TGF-β only (2ng/ml) and TGF-β (2ng/ml) with SMAD inhibitor (SB431542, 0.5 μM). β-actin is used as loading control.CC BY · PubMed Central
Figure 2 TGF-β1 induces dose- and time-dependent down-regulation of CAV-1 in human lung fibroblasts. A and B, Cultured IMR-90 cells were treated with or without TGF-β1 (2 ng/ml) for 24 h and total RNA was isolated. A, cDNA Superarray analysis was performed and mRNA expression levels of Cav-1 and cyclophilin A are shown. Densitometric ratios of Cav-1:cyclophilin A are also shown. B, Histogram of real-time RT-PCR for Cav-1 expression after treated with TGF-β1 (2 ng/ml for 24 h) using triplicate samples from at least three individual experiments, normalized to 18S as mean±S.E.M. *p<0.05 compared to control. C, IMR-90 cells were treated with TGF-β1 (0–5 ng/ml) for 24 h and cell lysates extracted. Cell lysates were subjected to SDS-PAGE and immunoblotted with an antibody against Cav-1; the blot was stripped and probed for β-tubulin. Densitometric ratios of Cav-1:β-tubulin are also shown on the right, as mean±S.E.M. D, IMR-90 cells were stimulated with TGF-β1 (2 ng/ml) for the indicated times. Cell lysates were subjected to SDS-PAGE and immunoblotted with an antibody against Cav-1; the blot was then stripped and probed for β-tubulin. Densitometric ratios of Cav-1:β-tubulin are shown on the right, as mean±S.E.M. Results are averages of at least three independent experiments.
Figure 2 TGF-β1 induces dose- and time-dependent down-regulation of CAV-1 in human lung fibroblasts. A and B, Cultured IMR-90 cells were treated with or without TGF-β1 (2 ng/ml) for 24 h and total RNA was isolated. A, cDNA Superarray analysis was performed and mRNA expression levels of Cav-1 and cyclophilin A are shown. Densitometric ratios of Cav-1:cyclophilin A are also shown. B, Histogram of real-time RT-PCR for Cav-1 expression after treated with TGF-β1 (2 ng/ml for 24 h) using triplicate samples from at least three individual experiments, normalized to 18S as mean±S.E.M. *p<0.05 compared to control. C, IMR-90 cells were treated with TGF-β1 (0–5 ng/ml) for 24 h and cell lysates extracted. Cell lysates were subjected to SDS-PAGE and immunoblotted with an antibody against Cav-1; the blot was stripped and probed for β-tubulin. Densitometric ratios of Cav-1:β-tubulin are also shown on the right, as mean±S.E.M. D, IMR-90 cells were stimulated with TGF-β1 (2 ng/ml) for the indicated times. Cell lysates were subjected to SDS-PAGE and immunoblotted with an antibody against Cav-1; the blot was then stripped and probed for β-tubulin. Densitometric ratios of Cav-1:β-tubulin are shown on the right, as mean±S.E.M. Results are averages of at least three independent experiments.CC BY · PubMed Central
Figure 3 Down-regulation of Cav-1 by TGF-β1 is mediated by p38 MAPK-dependent and SMAD-independent mechanisms. A, IMR-90 cells were treated with inhibitors of p38 MAPK (SB203580; 6 μM) or ALK5 (SB431542; 0.5 μM) for 30 min prior to treatment with or without TGF-β1 (2 ng/ml) for a period of 48 h. Cell lysates were extracted and Western immunoblotting performed with an antibody against Cav-1; the blot was then stripped and probed for β-tubulin. B, Densitometric analyses of blots in (A) showed as % inhibition of baseline Cav-1 protein expression levels treated with TGF-β1. *indicates effect of SB203580 to completely block the inhibitory effect of TGF-β1 on Cav-1 expression. Results are averages of at least three independent experiments. Data are presented as mean±S.E.M. C, IMR-90 cells stably transfected with a kinase-deficient p38 MAPK (pcDNA-p38KM) or control vector (pcDNA) were treated with or without TGF-β1 (2 ng/ml) for 24 h. Cell lysates were obtained and subjected to SDS-PAGE and immunoblotted for Cav-1 and α-smooth muscle actin (α-SMA); blots were stripped and probed for β-tubulin. D, IMR-90 cells stably expressing SMAD2 shRNA (pSU6H-shSMAD2) or control vector (pSU6H) were treated with/without TGF-β1 (2 ng/ml) for 24 h. Cell lysates were immunoblotted for SMAD2, Cav-1 and α-SMA. The blots were stripped and probed for β-tubulin.
Figure 3 Down-regulation of Cav-1 by TGF-β1 is mediated by p38 MAPK-dependent and SMAD-independent mechanisms. A, IMR-90 cells were treated with inhibitors of p38 MAPK (SB203580; 6 μM) or ALK5 (SB431542; 0.5 μM) for 30 min prior to treatment with or without TGF-β1 (2 ng/ml) for a period of 48 h. Cell lysates were extracted and Western immunoblotting performed with an antibody against Cav-1; the blot was then stripped and probed for β-tubulin. B, Densitometric analyses of blots in (A) showed as % inhibition of baseline Cav-1 protein expression levels treated with TGF-β1. *indicates effect of SB203580 to completely block the inhibitory effect of TGF-β1 on Cav-1 expression. Results are averages of at least three independent experiments. Data are presented as mean±S.E.M. C, IMR-90 cells stably transfected with a kinase-deficient p38 MAPK (pcDNA-p38KM) or control vector (pcDNA) were treated with or without TGF-β1 (2 ng/ml) for 24 h. Cell lysates were obtained and subjected to SDS-PAGE and immunoblotted for Cav-1 and α-smooth muscle actin (α-SMA); blots were stripped and probed for β-tubulin. D, IMR-90 cells stably expressing SMAD2 shRNA (pSU6H-shSMAD2) or control vector (pSU6H) were treated with/without TGF-β1 (2 ng/ml) for 24 h. Cell lysates were immunoblotted for SMAD2, Cav-1 and α-SMA. The blots were stripped and probed for β-tubulin.CC BY · PubMed Central
Figure 4 Over-expression of Cav-1 inhibits proliferation of human lung fibroblasts/myofibroblasts and abrogates the anti-apoptotic effects of TGF-β1. A, Human lung fibroblasts (IMR-90) were stably transfected with a plasmid encoding Cav-1 (pRC/CMV2-Cav1) or with empty vector (pRC/CMV2). Localization of Cav-1 protein was then analyzed by immunofluoresence staining with a rabbit polyclonal antibody to Cav-1. B, Stably-transfected cells described in (A) were treated with/without TGF-β1 (2 ng/ml) for 24 h. Cell lysates were obtained and subjected to immunoblotting for Cav-1, α-smooth muscle actin (α-SMA), and β-tubulin. C, Stably-transfected cells described in (A) were serum-deprived for 24 h and then treated with/without TGF-β1 (2 ng/ml) for 48 h followed by stimulation with 10% fetal bovine serum for 24 h. Cell numbers were assessed both prior to and after serum stimulation with an automated Coulter counter (n = 6 per group) as mean±S.E.M. *indicates p < 0.05 vs. control pRC/CMV2 “fibroblasts”. **indicates p < 0.05 vs. pRC/CMV2 “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. D, Cells in (C) were labeled with BrdU during the 24 h of serum stimulation (n = 6 per group). BrdU assays were performed as described in “Methods”. *indicates p < 0.05 vs. control pRC/CMV2 “fibroblasts”. **indicates p < 0.05 vs. pRC/CMV2 “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. E, Quiescent stably transfected IMR-90 cells described in (A) were treated with/without TGF-β1 (2 ng/ml) for 5 days in serum-free medium. Apoptosis assays using an ELISA for ssDNA (n = 6 for each group) were performed as described in “Methods”. *indicates p < 0.05 vs. control pRC/CMV2 “fibroblasts”. **indicates p < 0.01 vs. pRC/CMV2 “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments.
Figure 4 Over-expression of Cav-1 inhibits proliferation of human lung fibroblasts/myofibroblasts and abrogates the anti-apoptotic effects of TGF-β1. A, Human lung fibroblasts (IMR-90) were stably transfected with a plasmid encoding Cav-1 (pRC/CMV2-Cav1) or with empty vector (pRC/CMV2). Localization of Cav-1 protein was then analyzed by immunofluoresence staining with a rabbit polyclonal antibody to Cav-1. B, Stably-transfected cells described in (A) were treated with/without TGF-β1 (2 ng/ml) for 24 h. Cell lysates were obtained and subjected to immunoblotting for Cav-1, α-smooth muscle actin (α-SMA), and β-tubulin. C, Stably-transfected cells described in (A) were serum-deprived for 24 h and then treated with/without TGF-β1 (2 ng/ml) for 48 h followed by stimulation with 10% fetal bovine serum for 24 h. Cell numbers were assessed both prior to and after serum stimulation with an automated Coulter counter (n = 6 per group) as mean±S.E.M. *indicates p < 0.05 vs. control pRC/CMV2 “fibroblasts”. **indicates p < 0.05 vs. pRC/CMV2 “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. D, Cells in (C) were labeled with BrdU during the 24 h of serum stimulation (n = 6 per group). BrdU assays were performed as described in “Methods”. *indicates p < 0.05 vs. control pRC/CMV2 “fibroblasts”. **indicates p < 0.05 vs. pRC/CMV2 “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. E, Quiescent stably transfected IMR-90 cells described in (A) were treated with/without TGF-β1 (2 ng/ml) for 5 days in serum-free medium. Apoptosis assays using an ELISA for ssDNA (n = 6 for each group) were performed as described in “Methods”. *indicates p < 0.05 vs. control pRC/CMV2 “fibroblasts”. **indicates p < 0.01 vs. pRC/CMV2 “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments.CC BY · PubMed Central
Figure 5 shRNA knock-down of Cav-1 enhances fibroblast/myofibroblast proliferation and protects against serum deprivation-induced apoptosis. A, IMR-90 cells stably transfected with a plasmid encoding shRNA targeted against Cav-1 (pSU6H-shCav1) or with control plasmid (pSU6H) were treated with/without TGF-β1 (2 ng/ml) for 24 h. Cell lysates were obtained and Western blots for Cav-1, α-smooth muscle actin (α-SMA) and β-tubulin performed. B, Stably-transfected cells described in (A) were serum-deprived for 24 h and treated with/without TGF-β1 (2 ng/ml) for 48 h followed by stimulation with 10% FBS for 24 h. Cell counts were assessed both prior to and after serum stimulation with an automated Coulter counter (n = 6 per group) shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts”. **indicates p < 0.05 vs. pSU6H “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. C, Stably transfected cells described in (A) were serum-deprived for 24 h and treated with/without TGF-β1 (2 ng/ml) for 48 h followed by BrdU labeling for 24 h in the presence of 10% FBS (n = 6 per group) shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts”. Similar results were obtained from 3 independent experiments. D, Quiescent stably-transfected cells described in (A) were treated with/without TGF-β1 (2 ng/ml) for 5 days and apoptotic assay for ssDNA performed as described in “Methods” (n = 6 per group) shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts”. **indicates p < 0.05 vs. pSU6H “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments.
Figure 5 shRNA knock-down of Cav-1 enhances fibroblast/myofibroblast proliferation and protects against serum deprivation-induced apoptosis. A, IMR-90 cells stably transfected with a plasmid encoding shRNA targeted against Cav-1 (pSU6H-shCav1) or with control plasmid (pSU6H) were treated with/without TGF-β1 (2 ng/ml) for 24 h. Cell lysates were obtained and Western blots for Cav-1, α-smooth muscle actin (α-SMA) and β-tubulin performed. B, Stably-transfected cells described in (A) were serum-deprived for 24 h and treated with/without TGF-β1 (2 ng/ml) for 48 h followed by stimulation with 10% FBS for 24 h. Cell counts were assessed both prior to and after serum stimulation with an automated Coulter counter (n = 6 per group) shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts”. **indicates p < 0.05 vs. pSU6H “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. C, Stably transfected cells described in (A) were serum-deprived for 24 h and treated with/without TGF-β1 (2 ng/ml) for 48 h followed by BrdU labeling for 24 h in the presence of 10% FBS (n = 6 per group) shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts”. Similar results were obtained from 3 independent experiments. D, Quiescent stably-transfected cells described in (A) were treated with/without TGF-β1 (2 ng/ml) for 5 days and apoptotic assay for ssDNA performed as described in “Methods” (n = 6 per group) shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts”. **indicates p < 0.05 vs. pSU6H “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments.CC BY · PubMed Central
Figure 6 Blocking p38 MAPK inhibits myofibroblast proliferation. A, IMR-90 cells stably expressing a p38 MAPK dominant negative (pcDNA-p38KM) and cells stably transfected with an empty vector (pcDNA) were serum-starved for 24 h and treated with/without TGF- β1 (2 ng/ml) for 48 h followed by stimulation with 10% fetal bovine serum for 24 h (n = 6 per group), data shown as mean±S.E.M. *indicates p < 0.05 vs. control pcDNA “fibroblasts”. **indicates p < 0.01 vs. control pcDNA “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. B, Cells described in (A) were grown in 96-well plates and serum-starved for 24 h and treated with/without TGF- β1 (2 ng/ml) for 48 h followed by BrdU labeling for 24 h in the presence of 10% fetal bovine serum (n = 6 per group), data shown as mean±S.E.M. *indicates p < 0.05 vs. control pcDNA “fibroblasts”. **indicates p < 0.01 vs. control pcDNA “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. C, IMR-90 cells stably expressing SMAD2 shRNA and cells stably transfected with an empty vector (pSU6H) were serum-starved for 24 h and treated with/without TGF- β1 (2 ng/ml) for 48 h followed by stimulation with 10% fetal bovine serum for 24 h (n = 6 per group) data shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts” (no TGF-β1 pre-treatment). **indicates p < 0.05 vs. control pcDNA “myofibroblasts” (TGF-β1 pre-treated). D, Cells described in (C) were grown in 96-well plates and serum-starved for 24 h and treated with/without TGF- β1 (2 ng/ml) for 48 h followed by BrdU labeling for 24 h in the presence of 10% fetal bovine serum (n = 6 per group) data shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts” (no TGF-β1 pre-treatment). **indicates p < 0.05 vs. control pcDNA “myofibroblasts” (TGF-β1 pre-treated).
Figure 6 Blocking p38 MAPK inhibits myofibroblast proliferation. A, IMR-90 cells stably expressing a p38 MAPK dominant negative (pcDNA-p38KM) and cells stably transfected with an empty vector (pcDNA) were serum-starved for 24 h and treated with/without TGF- β1 (2 ng/ml) for 48 h followed by stimulation with 10% fetal bovine serum for 24 h (n = 6 per group), data shown as mean±S.E.M. *indicates p < 0.05 vs. control pcDNA “fibroblasts”. **indicates p < 0.01 vs. control pcDNA “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. B, Cells described in (A) were grown in 96-well plates and serum-starved for 24 h and treated with/without TGF- β1 (2 ng/ml) for 48 h followed by BrdU labeling for 24 h in the presence of 10% fetal bovine serum (n = 6 per group), data shown as mean±S.E.M. *indicates p < 0.05 vs. control pcDNA “fibroblasts”. **indicates p < 0.01 vs. control pcDNA “myofibroblasts” (TGF-β1 pre-treated). Similar results were obtained from 3 independent experiments. C, IMR-90 cells stably expressing SMAD2 shRNA and cells stably transfected with an empty vector (pSU6H) were serum-starved for 24 h and treated with/without TGF- β1 (2 ng/ml) for 48 h followed by stimulation with 10% fetal bovine serum for 24 h (n = 6 per group) data shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts” (no TGF-β1 pre-treatment). **indicates p < 0.05 vs. control pcDNA “myofibroblasts” (TGF-β1 pre-treated). D, Cells described in (C) were grown in 96-well plates and serum-starved for 24 h and treated with/without TGF- β1 (2 ng/ml) for 48 h followed by BrdU labeling for 24 h in the presence of 10% fetal bovine serum (n = 6 per group) data shown as mean±S.E.M. *indicates p < 0.05 vs. control pSU6H “fibroblasts” (no TGF-β1 pre-treatment). **indicates p < 0.05 vs. control pcDNA “myofibroblasts” (TGF-β1 pre-treated).CC BY · PubMed Central
Figure 7 Schematic representation of TGF-β1-activated signaling pathways mediating mesenchymal cell growth -suppressive and -promoting effects. TGF-β1 activates the cell surface TGF-β receptor(s) complex that leads to rapid activation of the canonical SMAD pathway as well as the SMAD-independent p38 MAPK pathway. Activation of the SMAD pathway is required for the induction of a cellular program of growth-arrest and myofibroblast differentiation. In contrast, activation of the p38 MAPK pathway, independently of SMAD2/3, is required the down-regulation of Cav-1 by TGF-β1. Down-regulation of Cav-1 by TGF-β1 “primes” differentiated myofibroblasts for enhanced proliferative responses to mitogens and resistance to apoptosis. These divergent TGF-β signaling pathways may explain, in part, the contextual effects of TGF-β1 as both a growth-inhibitor and –promoter on the same target (mesenchymal) cells.
Figure 7 Schematic representation of TGF-β1-activated signaling pathways mediating mesenchymal cell growth -suppressive and -promoting effects. TGF-β1 activates the cell surface TGF-β receptor(s) complex that leads to rapid activation of the canonical SMAD pathway as well as the SMAD-independent p38 MAPK pathway. Activation of the SMAD pathway is required for the induction of a cellular program of growth-arrest and myofibroblast differentiation. In contrast, activation of the p38 MAPK pathway, independently of SMAD2/3, is required the down-regulation of Cav-1 by TGF-β1. Down-regulation of Cav-1 by TGF-β1 “primes” differentiated myofibroblasts for enhanced proliferative responses to mitogens and resistance to apoptosis. These divergent TGF-β signaling pathways may explain, in part, the contextual effects of TGF-β1 as both a growth-inhibitor and –promoter on the same target (mesenchymal) cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 49

Metadata

Authors
Sanders, Y. Y., Cui, Z., Le Saux, C. J., Horowitz, J. C., Rangarajan, S., Kurundkar, A., Antony, V. B., & Thannickal, V. J.
Affiliations
  • University of Alabama at Birmingham (US)
  • University of Michigan (US)
Corresponding author
Thannickal, Victor J.
Venue
PLOS ONE
Published
2015-02-06
Volume
10
Issue
2
Pages
e0116995
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2057677504
Cited by
49
References
58
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 14 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 3 · 2015: 1
FWCI
2.17
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (HL114470)
  • National Institute on Aging (R01AG046210)
  • National Heart, Lung, and Blood Institute (P01HL114470, R01HL105489)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Keywords
TGF-β1, caveolin-1, myofibroblast differentiation, Smad-independent signaling, p38 MAPK, lung fibroblasts, cell proliferation, apoptosis resistance, serum deprivation, fibrosis
MeSH terms
Cell Survival, Humans, MAP Kinase Signaling System, p38 Mitogen-Activated Protein Kinases, Cell Proliferation, Caveolin 1, Smad Proteins, Transforming Growth Factor beta1, Myofibroblasts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SMAD-Independent Down-Regulation of Caveolin-1 by TGF-β: Effects on Proliferation and Survival of Myofibroblasts. https://app.cochat.ai/papers/10.1371/journal.pone.0116995
The paper
Sanders, Y. Y., Cui, Z., Le Saux, C. J., Horowitz, J. C., Rangarajan, S., Kurundkar, A., Antony, V. B., & Thannickal, V. J. (2015). SMAD-Independent Down-Regulation of Caveolin-1 by TGF-β: Effects on Proliferation and Survival of Myofibroblasts. PLOS ONE. https://doi.org/10.1371/journal.pone.0116995

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.